Neisseria gonorrhoeae ciprofloxacin susceptibility testing and gyrA targets

Lancet Microbe. 2023 Aug;4(8):e574. doi: 10.1016/S2666-5247(23)00149-0. Epub 2023 May 23.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Ciprofloxacin* / pharmacology
  • Gonorrhea* / drug therapy
  • Humans
  • Neisseria gonorrhoeae

Substances

  • Ciprofloxacin
  • Anti-Bacterial Agents